{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T04:33:18Z","timestamp":1725078798960},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T00:00:00Z","timestamp":1546646400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Agency for Medical Research and Development","award":["JP17ek0210082"],"award-info":[{"award-number":["JP17ek0210082"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00380-018-01333-6","type":"journal-article","created":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T13:22:52Z","timestamp":1546694572000},"page":"1024-1030","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost-effectiveness for prevention of thromboembolism by anticoagulants in non-valvular atrial fibrillation: additional analysis from the Hokuriku\u02d7Plus AF Registry"],"prefix":"10.1007","volume":"34","author":[{"name":"The Hokuriku\u02d7plus AF Registry Research Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Yamagishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toyonobu","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Furusho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenshi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,5]]},"reference":[{"key":"1333_CR1","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1253\/circj.CJ-66-0092","volume":"78","author":"JCS Joint Working Group","year":"2014","unstructured":"JCS Joint Working Group (2014) Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013). Circ J 78:1997\u20132021","journal-title":"Circ J"},{"key":"1333_CR2","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","volume":"130","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW, ACC, AHA Task Force Members (2014) 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130:2071\u20132104","journal-title":"Circulation"},{"key":"1333_CR3","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, ESC Scientific Document Group (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893\u20132962","journal-title":"Eur Heart J"},{"key":"1333_CR4","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139\u20131151","journal-title":"N Engl J Med"},{"key":"1333_CR5","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981\u2013992","journal-title":"N Engl J Med"},{"key":"1333_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, Investigatoes ROCKETAF (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883\u2013891","journal-title":"N Engl J Med"},{"key":"1333_CR7","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, \u0160pinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, ENGAGE AF\u02d7TIMI 48 Investigators (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093\u20132104","journal-title":"N Engl J Med"},{"key":"1333_CR8","unstructured":"J Health Welfare Stat 2017; 64: 63\u201366. \n                    http:\/\/www.mhlw.go.jp\/toukei\/list\/37-21.html\n                    \n                  . Accessed 1 Apr 2018"},{"key":"1333_CR9","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1253\/circj.CJ-16-1337","volume":"81","author":"Y Yamashita","year":"2017","unstructured":"Yamashita Y, Uozumi R, Hamatani Y, Esato M, Chun YH, Tsuji H, Wada H, Hasegawa K, Ogawa H, Abe M, Morita S, Akao M (2017) Current status and outcomes of direct oral anticoagulant use in real-world atrial fibrillation patients\u2014Fushimi AF registry. Circ J 81:1278\u20131285","journal-title":"Circ J"},{"key":"1333_CR10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jjcc.2012.12.002","volume":"61","author":"M Akao","year":"2013","unstructured":"Akao M, Chun YH, Wada H, Esato M, Hashimoto T, Abe M, Hasegawa K, Tsuji H, Furuke K, On behalf of the Fushimi AF Registry investigators (2013) Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry. J Cardiol 61:260\u2013266","journal-title":"J Cardiol"},{"key":"1333_CR11","doi-asserted-by":"crossref","unstructured":"Hayashi K, Tsuda T, Nomura A, Fujino N, Nohara A, Sakata K, Konno T, Nakanishi C, Tada H, Nagata Y, Teramoto R, Tanaka Y, Kawashiri MA, Yamagishi M, on behalf of the Hokuriku-Plus AF Registry Investigators (2018) Impact of B-type natriuretic peptide level on risk stratification of thromboembolism and death in patients with nonvalvular atrial fibrillation: the Hokuriku-plus AF Registry. Circ J 82:1271\u20131278","DOI":"10.1253\/circj.CJ-17-1085"},{"key":"1333_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0038-1651587","volume":"69","author":"FR Rosendaal","year":"1993","unstructured":"Rosendaal FR, Cannegieter SC, van der Meer FJ, Bri\u00ebt E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69:236\u2013239","journal-title":"Thromb Haemost"},{"key":"1333_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.joa.2016.11.003","volume":"33","author":"Y Okumura","year":"2017","unstructured":"Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, Oiwa K, Matsumoto M, Kojima T, Hanada S, Nomoto K, Arima K, Takahashi F, Kotani T, Ikeya Y, Fukushima S, Itoh S, Kondo K, Chiku M, Ohno Y, Onikura M, Hirayama A, The SAKURA AF Registry Investigators (2017) Current use of direct oral anticoagulants for atrial fibrillation in Japan: finding from SAKURA AF Registry. J Arrhythm 33:289\u2013296","journal-title":"J Arrhythm"},{"key":"1333_CR14","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","volume":"285","author":"BF Gage","year":"2001","unstructured":"Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864\u20132870","journal-title":"JAMA"},{"key":"1333_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263\u2013272","journal-title":"Chest"},{"key":"1333_CR16","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:1093\u20131100","journal-title":"Chest"},{"key":"1333_CR17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(15)60245-8","volume":"386","author":"FW Verheugt","year":"2015","unstructured":"Verheugt FW, Granger CB (2015) Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet 386:303\u2013310","journal-title":"Lancet"},{"key":"1333_CR18","first-page":"151","volume":"29","author":"M Hori","year":"2011","unstructured":"Hori M, Koretsune Y, Yasaka M, Shimada I, Fukuda T (2011) The analysis of medical cost for prevention of stroke by dabigatran etexilate in patients with non-valvular atrial fibrillation. Pharma Med 29:151\u2013164","journal-title":"Pharma Med"},{"key":"1333_CR19","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1253\/circj.CJ-14-1245","volume":"79","author":"Y Hamatani","year":"2015","unstructured":"Hamatani Y, Ogawa H, Uozumi R, Iguchi M, Yamashita Y, Esato M, Chun YH, Tsuji H, Wada H, Hasegawa K, Abe M, Morita S, Akao M (2015) Low Body Weight is associated with the incidence of stroke in atrial fibrillation patients\u2014insight from the Fushimi AF registry. Circ J 79:1009\u20131017","journal-title":"Circ J"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-018-01333-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00380-018-01333-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-018-01333-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,5]],"date-time":"2020-01-05T00:20:04Z","timestamp":1578183604000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00380-018-01333-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,5]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["1333"],"URL":"https:\/\/doi.org\/10.1007\/s00380-018-01333-6","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"type":"print","value":"0910-8327"},{"type":"electronic","value":"1615-2573"}],"subject":[],"published":{"date-parts":[[2019,1,5]]},"assertion":[{"value":"17 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors received honoraria for lectures from Daiichi-Sankyo Co. Ltd., Boehringer Ingelheim Japan Co. Ltd., and received scholarship fund from Boehringer Ingelheim Japan Co. Ltd., Bayer Co. Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}